Omega Diagnostics Group (ODX.L) Preliminary report published by Ulster University

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the publication of the preliminary report of an independent evaluation of Abc-19TM by Ulster University.

The independent report compares three commercially available immunoassays to evaluate performance metrics for the AbC-19TM lateral flow test, which is developed by the UK-RTC. The report notes the lack of a well-accepted gold standard assay against which to measure any newly developed immunoassay designed to detect antibodies to SARS-CoV-2.

To overcome these challenges, a ‘pseudo gold standard’ system was established against which to analyse the sensitivity and specificity of each of the three commercially available immunoassays using a well-characterised serology sample set to evaluate performance metrics for the AbC-19TM test. Using the ‘pseudo gold standard’ system the report concludes that the UK-RTC AbC-19 lateral flow immunoassay shows a sensitivity of 97.70% (95.72%-99.34%) and specificity of 100% (100.00-100.00%).

A link to the preliminary report can be found here:

Follow Share Talk

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned
Share via
Copy link
Malcare WordPress Security